Published in Vaccine Weekly, November 27th, 2002
The independent study was authored by scientists from the Memorial Sloan-Kettering Cancer Center, Laboratories of Tumor Vaccinology and Bioorganic Chemistry.
The paper addressed the development of novel synthetic multivalent vaccines containing different tumor-associated carbohydrate antigens, and compared the capacity of QS-21 and the related but stable and significantly less toxic GPI-0100 to enhance an antibody...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.